Insights into the pathophysiology of ST-Elevation myocardial infarction

American Heart Journal

Volumn 151, Issue 6 SUPPL., 2006, Pages

  Brener, Sorin J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; LYMPHOTOXIN; THROMBOSPONDIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CORONARY ARTERY THROMBOSIS; DNA POLYMORPHISM; DNA SEQUENCE; GENE IDENTIFICATION; HEART INFARCTION; HEREDITY; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM; VASCULITIS;

ATHEROSCLEROSIS; BLOOD COAGULATION; CORONARY THROMBOSIS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; RISK FACTORS;

EID: 33744920091     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.04.007     Document Type: Review

References (37)

1. Thom T., Haase N., Rosamond W., et al. Heart Disease and Stroke Statistics-2006 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Source: American Heart Association Web site. Updated (2006) [Accessed: January 17]
2. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110 (2004) e82-e292
3. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
4. Libby P. Changing concepts of atherogenesis. J Intern Med 247 (2000) 349-358
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
6. Ambrose J.A., and Fuster V. The risk of coronary occlusion is not proportional to the prior severity of coronary stenoses. Heart 79 (1998) 3-4
7. Little W.C. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol 66 (1990) 44G-47G
8. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 (2001) 365-372
9. Libby P. Molecular bases of the acute coronary syndromes. Circulation 91 (1995) 2844-2850
10. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
11. Fuster V., Moreno P.R., Fayad Z.A., et al. Atherothrombosis and high-risk plaque. Part I: evolving concepts. J Am Coll Cardiol 46 (2005) 937-954
12. Aikawa M., and Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 13 (2004) 125-138
13. Maseri A., and Fuster V. Is there a vulnerable plaque?. Circulation 107 (2003) 2068-2071
14. Alexander J.H., and Harrington R.A. Antiplatelet and antithrombin therapies in the acute coronary syndromes. Curr Opin Cardiol 12 (1997) 427-437
15. Marcus A.J., Safier L.B., Broekman M.J., et al. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Thromb Haemost 74 (1995) 213-217
16. Marcus A.J., Broekman M.J., Drosopoulos J.H., et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 99 (1997) 1351-1360
17. Ferguson J.J. The physiology of normal platelet function. In: Ferguson J.J., Chronos N., and Harrington R.A. (Eds). Antiplatelet therapy in clinical practice (2000), Martin Dunitz, London 15-35
18. Kroll M.H., Harris T.S., Moake J.L., et al. von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest 88 (1991) 1568-1573
19. Shattil S.J., Hoxie J.A., Cunningham M., et al. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 260 (1985) 11107-11114
20. Wilcox J.N., Smith K.M., Schwartz S.M., et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 86 (1989) 2839-2843
21. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103 (2001) 1813-1818
22. Ridker P.M., Wilson P.W., and Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 109 (2004) 2818-2825
23. Foussas S.G., Zairis M.N., Lyras A.G., et al. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes. Am J Cardiol 96 (2005) 533-537
24. Kinjo K., Sato H., Ohnishi Y., et al. Impact of high-sensitivity C-reactive protein on predicting long-term mortality of acute myocardial infarction. Am J Cardiol 91 (2003) 931-935
25. Lincoff A.M., Kereiakes D.J., Mascelli M.A., et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 104 (2001) 163-167
26. Lindahl B., Toss H., Siegbahn A., et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 343 (2000) 1139-1147
27. Szmitko P.E., Wang C.H., Weisel R.D., et al. New markers of inflammation and endothelial cell activation: Part I. Circulation 108 (2003) 1917-1923
28. Buffon A., Biasucci L.M., Liuzzo G., et al. Widespread coronary inflammation in unstable angina. N Engl J Med 347 (2002) 5-12
29. Schonbeck U., Sukhova G.K., Shimizu K., et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 97 (2000) 7458-7463
30. Song Y., Stampfer M.J., and Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 141 (2004) 137-147
31. Topol E.J., McCarthy J., Gabriel S., et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 104 (2001) 2641-2644
32. Wang Q. Advances in the genetic basis of coronary artery disease. Curr Atheroscler Rep 7 (2005) 235-241
33. Yamada A., Ichihara S., Murase Y., et al. Lack of association of polymorphisms of the lymphotoxin alpha gene with myocardial infarction in Japanese. J Mol Med 82 (2004) 477-483
34. Helgadottir A., Manolescu A., Helgason A., et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 38 (2006) 68-74
35. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
36. Hakonarson H., Thorvaldsson S., Helgadottir A., et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293 (2005) 2245-2256
37. Brown M.S., and Goldstein J.L. Heart attacks: gone with the century?. Science 272 (1996) 629